{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-026651","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.956319+00:00","generated_at":"2026-05-26T04:23:39.909439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance","bullets":["Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).","Q4 net loss $(5.9)M vs $(9.2)M; adjusted net earnings $1.3M ($0.03/share) vs adjusted loss $(4.8M).","LAL procedure volume 29,069 units (+61% YoY); LDD installed base 971 (+46% YoY).","FY2025 guidance: revenue $185-197M (32-41% growth), gross margin 71-73%, operating expenses $165-170M.","Cash and investments $237.2M; no debt mentioned."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-026651","json":"https://secwatch.observer/filing/0000950170-25-026651.json","markdown":"https://secwatch.observer/filing/0000950170-25-026651.md","text":"https://secwatch.observer/filing/0000950170-25-026651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025026651/0000950170-25-026651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025026651/rxst-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:23:39.909439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}